In this episode of Yet Another Value Podcast, host Andrew Walker speaks with Jingshu Zhang from Guinea Value about Fiserv (FISV) and the broader payments sector. They examine the recent drawdown across payment companies, addressing concerns around AI disruption, regulation, and macro pressures. Jingshu outlines Fiserv’s business structure across financial institutions and merchant solutions, while detailing the impact of leadership changes and operational missteps under prior management. The discussion highlights the ongoing strategic reset, new executive hires from JPMorgan, and extensive on-the-ground research into Clover’s positioning. They also debate capital allocation, insider alignment, activist involvement, and valuation, exploring whether Fiserv represents a turnaround opportunity or a declining legacy asset.

See Shu's substack here: https://jingshu.substack.com/

See Trata's FISV transcript here: https://www.trata.com/fisv

___________________________________________________________

[00:00:00] Podcast intro and guest background

[00:03:56] Payments sector under broad pressure

[00:05:32] Market fears impacting payment companies[00:06:51] AI risks debated in payments

[00:11:38] Structural advantages protect payment networks

[00:12:49] Capital allocation concerns across peers

[00:17:19] Fiserv business segments overview

[00:18:59] Leadership change and prior mismanagement

[00:24:23] Strategic reset and growth normalization

[00:27:49] Variant perception and investment thesis

[00:28:50] New executive team and talent inflow

[00:34:55] Clover positioning versus competitors

[00:36:20] Field research from restaurant interviews

[00:42:01] Valuation framework and earnings outlook

[00:46:14] Insider alignment and incentives discussion

[00:53:34] Organizational culture and employee sentiment

[00:58:30] Activist involvement and strategic options

Links:

Yet Another Value Blog - https://www.yetanothervalueblog.com

See our legal disclaimer here: https://www.yetanothervalueblog.com/p/legal-and-disclaimer

Production and editing by The Podcast Consultant - https://thepodcastconsultant.com/

Sean Emory of Avory & Co analyzes Clear Security, a biometric identity platform operating in airports nationwide. They examine the company’s subscription model, competitive positioning against TSA and airlines, and the impact of recent TSA disruptions on demand. The discussion covers Clear’s pricing power, partnerships with credit card providers like Amex, and the durability of its airport footprint. Sean also outlines a developing enterprise identity segment and its potential role in future growth. The conversation addresses valuation, risks, and whether Clear’s moat can sustain long-term returns. ___________________________________________________________________

[00:00:00] Andrew introduces Clear Security debate

[00:03:54] Clear explained: biometric airport platform

[00:07:11] Growth limits and line congestion[

00:10:00] TSA PreCheck economics and strategy

[00:14:04] Competition from TSA and airlines

[00:18:15] Airport partnerships and revenue sharing

[00:23:12] Market missing enterprise identity opportunity

[00:28:48] Debate on enterprise business significance

[00:34:11] TSA disruption impact on stock

[00:39:36] Valuation and growth assumptions

[00:43:24] Pricing power and customer behavior

[00:49:21] Amex partnership risks and dynamics

[00:56:12] Capital allocation and cash usage

[01:00:56] Long-term identity and AI implications

Links:

Yet Another Value Blog - https://www.yetanothervalueblog.com

See our legal disclaimer here: https://www.yetanothervalueblog.com/p/legal-and-disclaimer

Production and editing by The Podcast Consultant - https://thepodcastconsultant.com/

In this episode of Yet Another Value Podcast, host Andrew Walker is joined by Andy Summers, CIO of Summers Value, to discuss Theravance (TBPH; disclosure: long). Both share their perspectives as shareholders while examining the company’s setup following a failed Phase 3 trial. They break down Theravance’s remaining asset, the COPD drug Yupelri, and its long-term royalty potential. The discussion covers the company’s balance sheet strength, cost reductions, and ongoing strategic review process. Andy outlines valuation assumptions, including U.S. royalties, China opportunity, and tax attributes, while also assessing potential buyers and deal dynamics. They also explore downside scenarios if a sale does not occur and why the situation presents an asymmetric risk-reward profile.

___________________________________________________

[00:00:00] Podcast introduction and sponsor mention

[00:02:41] Overview of Theravance business model

[00:05:02] Phase three failure stock decline

[00:06:56] Activist involvement and ownership concentration

[00:09:01] Strategic review process and acceleration

[00:09:49] Breakdown of balance sheet and cash

[00:12:49] Discussion on downside protection and sizing

[00:14:11] Yupelri drug positioning and growth

[00:15:59] Patent protection timeline through 2039

[00:17:13] Valuation of royalty stream

[00:18:08] Sum-of-parts valuation discussion

[00:18:49] China opportunity and royalty upside

[00:24:22] Strategic buyers and acquisition dynamics

[00:28:22] Concerns about limited bidding competition

[00:30:57] Potential alternative buyers and synergies

[00:35:08] What market may be missing

[00:35:57] Ireland tax asset potential value

[00:38:03] Scenario if company not sold

[00:41:30] Potential management change outcomes

[00:43:22] Asymmetric risk reward summary

[00:44:24] Timing expectations for potential deal

Links:

Yet Another Value Blog - https://www.yetanothervalueblog.com

See our legal disclaimer here: https://www.yetanothervalueblog.com/p/legal-and-disclaimer

Production and editing by The Podcast Consultant - https://thepodcastconsultant.com/